RU2017101236A - Способы и устройства для лечения патологических нарушений в заднем сегменте глаза - Google Patents

Способы и устройства для лечения патологических нарушений в заднем сегменте глаза Download PDF

Info

Publication number
RU2017101236A
RU2017101236A RU2017101236A RU2017101236A RU2017101236A RU 2017101236 A RU2017101236 A RU 2017101236A RU 2017101236 A RU2017101236 A RU 2017101236A RU 2017101236 A RU2017101236 A RU 2017101236A RU 2017101236 A RU2017101236 A RU 2017101236A
Authority
RU
Russia
Prior art keywords
drug
eye
dose
antibody
medicinal
Prior art date
Application number
RU2017101236A
Other languages
English (en)
Russian (ru)
Other versions
RU2017101236A3 (enExample
Inventor
Кристофер Джон Брукс
Рафаэль Виктор Андино
Самиркумар Пател
Дэниел Уайт
Гленн НОРОНА
Original Assignee
Клиасайд Байомедикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Клиасайд Байомедикал, Инк. filed Critical Клиасайд Байомедикал, Инк.
Publication of RU2017101236A publication Critical patent/RU2017101236A/ru
Publication of RU2017101236A3 publication Critical patent/RU2017101236A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
RU2017101236A 2014-06-17 2015-06-17 Способы и устройства для лечения патологических нарушений в заднем сегменте глаза RU2017101236A (ru)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462013209P 2014-06-17 2014-06-17
US62/013,209 2014-06-17
US201462018148P 2014-06-27 2014-06-27
US62/018,148 2014-06-27
US201462063792P 2014-10-14 2014-10-14
US62/063,792 2014-10-14
US201562155367P 2015-04-30 2015-04-30
US62/155,367 2015-04-30
US201562156802P 2015-05-04 2015-05-04
US62/156,802 2015-05-04
PCT/US2015/036299 WO2015195842A1 (en) 2014-06-17 2015-06-17 Methods and devices for treating posterior ocular disorders

Publications (2)

Publication Number Publication Date
RU2017101236A true RU2017101236A (ru) 2018-07-17
RU2017101236A3 RU2017101236A3 (enExample) 2019-05-16

Family

ID=54936084

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017101236A RU2017101236A (ru) 2014-06-17 2015-06-17 Способы и устройства для лечения патологических нарушений в заднем сегменте глаза

Country Status (12)

Country Link
US (1) US20180042765A1 (enExample)
EP (1) EP3157463A4 (enExample)
JP (2) JP6774340B2 (enExample)
KR (1) KR102511477B1 (enExample)
CN (1) CN107072765A (enExample)
AU (1) AU2015277133A1 (enExample)
BR (1) BR112016029864A2 (enExample)
CA (1) CA2952822A1 (enExample)
IL (1) IL249602A0 (enExample)
MX (1) MX2016016836A (enExample)
RU (1) RU2017101236A (enExample)
WO (1) WO2015195842A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
JP6548229B2 (ja) 2014-02-12 2019-07-24 オービット・バイオメディカル・リミテッドＯｒｂｉｔ Ｂｉｏｍｅｄｉｃａｌ Ｌｉｍｉｔｅｄ 治療薬の脈絡膜上投与のための方法及び装置
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
US10399713B2 (en) 2016-01-19 2019-09-03 Dr. Py Institute Llc Devices and methods for formulation processing
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
JP7332602B2 (ja) * 2017-12-28 2023-08-23 センジュ ユーエスエー、インコーポレイテッド 経皮薬物送達システムおよびその使用方法
WO2019161272A1 (en) 2018-02-15 2019-08-22 North Carolina State University Synthesis of micron and nanoscale carbon spheres and structures using hydrothemal carbonization
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019173211A1 (en) * 2018-03-05 2019-09-12 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of csf1r
US20210236336A1 (en) * 2018-05-09 2021-08-05 North Carolina State University Applicator for corneal therapeutics
US11039954B2 (en) * 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
CN110009626A (zh) * 2019-04-11 2019-07-12 北京百度网讯科技有限公司 用于生成图像的方法和装置
CA3136814A1 (en) 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN119745879A (zh) * 2020-02-19 2025-04-04 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
CN115803070A (zh) * 2020-07-17 2023-03-14 艾斯曲尔医疗公司 微剂量给药装置及组装该微剂量给药装置的方法
US20240000443A1 (en) * 2020-11-30 2024-01-04 Visionaire Products, Inc. Needle and collection device for ocular biopsy and methods of use
JP2023551679A (ja) * 2020-12-02 2023-12-12 テリオス ファーマ， インコーポレイテッド 眼科疾患を治療するための方法及び組成物
WO2022133251A1 (en) * 2020-12-17 2022-06-23 Mobius Therapeutics, Llc Injection apparatus and method of use
CN113101502B (zh) * 2021-03-01 2023-01-17 李特 一种耳鼻喉科用治疗装置
CN113198003A (zh) * 2021-06-22 2021-08-03 万永年 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
CA3242886A1 (en) * 2022-01-06 2023-07-13 Clearside Biomedical, Inc. Compositions and methods for treating macular edema associated with uveitis
TWI890114B (zh) * 2022-08-16 2025-07-11 美商奧伊斯特普安生物製藥公司 將藥物無菌地轉移至藥物遞送裝置的藥物轉移系統及方法
JP2025533557A (ja) * 2022-09-23 2025-10-07 イノキュラス・ベンチャーズ・リミティド・ライアビリティ・カンパニー ドライアイの処置
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025015046A1 (en) * 2023-07-10 2025-01-16 Eden Ophthalmic Pte Ltd. Liposomal formulations of corticosteroids and uses thereof
WO2025179248A1 (en) * 2024-02-23 2025-08-28 Oculogenex Inc. Microneedle device for intraocular injections and methods of using the same
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003765A1 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2951938B1 (ja) * 1998-03-19 1999-09-20 日本ケミカルリサーチ株式会社 薬剤溶解機構を内蔵した注射器
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008070479A2 (en) * 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8083759B2 (en) * 2007-11-02 2011-12-27 Refocus Ocular, Inc. Apparatuses and methods for forming incisions in ocular tissue
US8221353B2 (en) * 2008-10-21 2012-07-17 KMG Pharma, Inc Intravitreal injection device and system
WO2012019136A2 (en) * 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
US20120101475A1 (en) * 2010-10-21 2012-04-26 Meridian Medical Technologies, Inc. High Efficiency Auto-Injector
EP2578260A1 (en) * 2011-10-07 2013-04-10 Sanofi-Aventis Deutschland GmbH Apparatus for intraocular injection
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents

Also Published As

Publication number Publication date
JP2020063236A (ja) 2020-04-23
KR20170039128A (ko) 2017-04-10
BR112016029864A2 (pt) 2017-08-22
EP3157463A1 (en) 2017-04-26
CN107072765A (zh) 2017-08-18
JP6774340B2 (ja) 2020-10-21
WO2015195842A1 (en) 2015-12-23
RU2017101236A3 (enExample) 2019-05-16
MX2016016836A (es) 2017-07-27
KR102511477B1 (ko) 2023-03-16
US20180042765A1 (en) 2018-02-15
CA2952822A1 (en) 2015-12-23
EP3157463A4 (en) 2018-02-21
JP2017524677A (ja) 2017-08-31
IL249602A0 (en) 2017-02-28
AU2015277133A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JP2017524677A5 (enExample)
Lynch et al. Bevacizumab for neovascular ocular diseases
JP2020063236A (ja) 後眼部障害を処置するための方法およびデバイス
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
Chiquet et al. Postoperative ocular inflammation: a single subconjunctival injection of XG-102 compared to dexamethasone drops in a randomized trial
AU2017206114A1 (en) Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
Cohen et al. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
AU2013342275A1 (en) Methods and devices for the treatment of ocular diseases in human subjects
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
CN115066236A (zh) 糖尿病性黄斑水肿和视敏度受损的治疗
WO2023144699A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
Höhn et al. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application
Seo et al. Intravitreal bevacizumab for treatment of diabetic macular edema
US20230054032A1 (en) Compositions and methods for treating ocular disease
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
Frenkel et al. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%
Ryoo et al. Regression of iris neovascularization after subconjunctival injection of bevacizumab
US20140178451A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
Bulla et al. Real-world safety and efficacy of Anti-VEGF treatment in Brazil
Morales-Canton et al. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes
Karakahya Anterior chamber paracentesis offers a less painful experience during intravitreal anti-vascular endothelial growth factor administration: An intraindividual study
Yeniad et al. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases
Ferguson et al. Varenicline solution nasal spray 0.03 Mg for the treatment of dry eye disease following photorefractive keratectomy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191216